Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

K Lindemann; PJ Beale; E Rossi; JC Goh; MM Vaughan; ME Tenney; JK Martyn; D Sommeijer; JL Iglesias; G Kremmidiotis; J Simpson; E Doolin; TC Lavranos; A Leske; AS Veillard; D Espinoza; MR Stockler; D Rischin

Journal article

Phase I study of BNC105P, carboplatin and gemcitabine in partially platinum-sensitive ovarian cancer patients in first or second relapse (ANZGOG-1103)

K Lindemann, PJ Beale, E Rossi, JC Goh, MM Vaughan, ME Tenney, JK Martyn, D Sommeijer, JL Iglesias, G Kremmidiotis, J Simpson, E Doolin, TC Lavranos, A Leske, AS Veillard, D Espinoza, MR Stockler, D Rischin

Cancer Chemotherapy and Pharmacology | SPRINGER | Published : 2019

DOI: 10.1007/s00280-018-3706-5

Abstract

Purpose: The primary objective of this study was to determine the recommended dose of the vascular disrupting agent, BNC105P, in combination with gemcitabine and carboplatin in patients with ovarian cancer in first or second relapse with a minimum 4 month progression-free interval after last platinum. Methods: Patients received carboplatin AUC4 on day 1 in combination with escalating doses of 800 or 1000 mg/m 2 gemcitabine on days 1 and 8 and escalating doses of 12 or 16 mg/m 2 BNC105P on days 2 and 9 every 21 days for a maximum for six cycles. Maintenance treatment with 16 mg/m 2 BNC105P treatment continued for a maximum of six additional cycles. Patients were followed for safety and anti-t..

View full abstract